Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 362 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Gilead Sciences Inc | GILD | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.14 | 0.22% | 64.41 | 05:38:10 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 64.27 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 15 | 362 | - | 62.07 - 87.865 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 05:28:48 | formt | 138 | US$ 64.41 | USD |
Gilead Sciences (GILD) Options Flow Summary
Gilead Sciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 80.07B | 1.25B | - | 27.12B | 5.67B | 4.55 | 14.13 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Gilead Sciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GILD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 65.34 | 65.5515 | 62.07 | 64.04 | 8,172,051 | -0.93 | -1.42% |
| 1 Month | 64.78 | 68.37 | 62.07 | 65.85 | 6,429,355 | -0.37 | -0.57% |
| 3 Months | 74.88 | 76.21 | 62.07 | 68.56 | 6,974,097 | -10.47 | -13.98% |
| 6 Months | 77.29 | 87.865 | 62.07 | 73.85 | 7,180,700 | -12.88 | -16.66% |
| 1 Year | 77.99 | 87.865 | 62.07 | 75.32 | 6,448,204 | -13.58 | -17.41% |
| 3 Years | 65.96 | 89.74 | 57.165 | 71.61 | 7,097,593 | -1.55 | -2.35% |
| 5 Years | 62.50 | 89.74 | 56.56 | 70.33 | 8,291,199 | 1.91 | 3.06% |
Gilead Sciences Description
| Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. |
